Contemporary Therapy Outcomes with Brentuximab vedotin, Bendamustine and Checkpoint inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
Giles, M. Shotton, R. Phillips, E. Linton, K.
Giles, M.
Shotton, R.
Phillips, E.
Linton, K.
Citations
Altmetric:
Abstract
Authors
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Giles M, Shotton R, Phillips E, Linton K. Contemporary Therapy Outcomes with Brentuximab vedotin, Bendamustine and Checkpoint inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma. British journal of haematology. 2025 APR;206. PubMed PMID: WOS:001517858300097. English.